Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma

International uniform response criteria for multiple myeloma

Brian G.M. Durie, J-L Harousseau, Jesús F. San Miguel et al. · Leukemia · 2006 · 2.6K citations

Medicine, Hematology, Oncology +12

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.

Régis Bataille, Gaëtan Jégo, Nelly Robillard et al. · PubMed · 2006 · 225 citations

Medicine, Hematology, Oncology +13

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

Gema Mateo, María-Ángeles Montalbán, María‐Belén Vídriales et al. · Journal of Clinical Oncology · 2008 · 210 citations · Full text

Medicine, Hematology, Oncology +16

The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma

Catherine Pellat‐Deceunynck, Gaëtan Jégo, Denis Puthier et al. · Leukemia · 1998 · 193 citations

Medicine, Hematology, Oncology +14

CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma

Nelly Robillard, Hervé Avet‐Loiseau, Richard Garand et al. · Blood · 2003 · 185 citations · Full text

Medicine, Immunology, Pathology +12